| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Haystack MRD™ Monitoring
Test Code13151
CPT Codes
81479<br><strong>This test is not available for New York patient testing</strong>
Preferred Specimen
30 mL whole blood collected in 3 Streck cell-free (black/tan tiger-top) glass tubes
Minimum Volume
24 mL
Instructions
Sample collection using a straight needle is preferred. Use Streck tubes only. All tubes must be filled completely. Gently invert tube at least 8 times immediately after draw.
Please note: If Hospital Discharge Date is not populated, outpatient treatment is assumed.
Please note: If Hospital Discharge Date is not populated, outpatient treatment is assumed.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: Unacceptable
Frozen: Unacceptable
Refrigerated: Unacceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis
Methodology
Next Generation Sequencing
Setup Schedule
Set-up: Daily; Report available: 7-14 days
Clinical Significance
Haystack MRD™ is a tumor-informed minimal residual disease (MRD) test that analyzes circulating tumor DNA (ctDNA) in the blood of patients who have been diagnosed with cancer or a previous diagnosis of cancer. The test requires identification of tumor-specific mutations for the development of a personalized ctDNA assay (Haystack MRD™ Personalization). The personalized assay is used to measure ctDNA to identify the presence of cancer in an initial blood sample (Haystack MRD™ Baseline) and at subsequent timepoints (Haystack MRD™ Monitoring).
Circulating tumor DNA (ctDNA) in blood is measured at specified intervals, after baseline, using the tumor- specific, personalized assay developed in the previous Haystack MRD™ Personalization step. Detection of ctDNA at one or multiple timepoint(s) may inform a patient's response to therapy and/or indicate cancer recurrence.
Circulating tumor DNA (ctDNA) in blood is measured at specified intervals, after baseline, using the tumor- specific, personalized assay developed in the previous Haystack MRD™ Personalization step. Detection of ctDNA at one or multiple timepoint(s) may inform a patient's response to therapy and/or indicate cancer recurrence.
